NO984555D0 - T1- Lever - Google Patents

T1- Lever

Info

Publication number
NO984555D0
NO984555D0 NO984555A NO984555A NO984555D0 NO 984555 D0 NO984555 D0 NO 984555D0 NO 984555 A NO984555 A NO 984555A NO 984555 A NO984555 A NO 984555A NO 984555 D0 NO984555 D0 NO 984555D0
Authority
NO
Norway
Prior art keywords
contrast
magnetic particles
weighted image
vasculature
organ
Prior art date
Application number
NO984555A
Other languages
English (en)
Other versions
NO984555L (no
Inventor
Anne Kjersti Fahlvik
Original Assignee
Nycomed Imaging As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Imaging As filed Critical Nycomed Imaging As
Publication of NO984555D0 publication Critical patent/NO984555D0/no
Publication of NO984555L publication Critical patent/NO984555L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
    • A61K49/186—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA the organic macromolecular compound being polyethyleneglycol [PEG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO984555A 1996-04-01 1998-09-29 T1- Lever NO984555L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/625,223 US5855868A (en) 1996-04-01 1996-04-01 Method of T1 -weighted resonance imaging of RES organs
PCT/GB1997/000886 WO1997036617A2 (en) 1996-04-01 1997-03-27 Method of t1-weighted magnetic resonance imaging of res organs

Publications (2)

Publication Number Publication Date
NO984555D0 true NO984555D0 (no) 1998-09-29
NO984555L NO984555L (no) 1998-09-29

Family

ID=24505090

Family Applications (1)

Application Number Title Priority Date Filing Date
NO984555A NO984555L (no) 1996-04-01 1998-09-29 T1- Lever

Country Status (14)

Country Link
US (1) US5855868A (no)
EP (1) EP0896546B1 (no)
JP (1) JP4361970B2 (no)
KR (1) KR20000005194A (no)
CN (1) CN1219135A (no)
AT (1) ATE228017T1 (no)
AU (1) AU704926B2 (no)
CA (1) CA2250818A1 (no)
DE (1) DE69717269T2 (no)
EA (1) EA000796B1 (no)
ES (1) ES2188924T3 (no)
IL (1) IL126412A0 (no)
NO (1) NO984555L (no)
WO (1) WO1997036617A2 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT81498B (pt) * 1984-11-23 1987-12-30 Schering Ag Processo para a preparacao de composicoes para diagnostico contendo particulas magneticas
WO1998005430A1 (de) 1996-08-05 1998-02-12 Schering Aktiengesellschaft Vorrichtung und verfahren zur abtrennung magnetischer materialien aus pharmazeutischen zubereitungen, deren ausgangs- oder zwischenprodukten sowie mit hilfe dieser vorrichtung hergestellte mittel
WO2001074245A1 (en) * 2000-03-31 2001-10-11 Amersham Health As Method of magnetic resonance imaging
US7082326B2 (en) * 2000-03-31 2006-07-25 Amersham Health As Method of magnetic resonance imaging
KR20020075513A (ko) * 2001-03-24 2002-10-05 조용덕 전기분해법을 이용한 폐수의 처리방법
DE102004022061A1 (de) 2004-05-05 2005-12-08 Siemens Ag Verfahren zur verbesserten interventionallen Bildgebung in der Magnet-Resonanz-Tomographie
US20100259259A1 (en) * 2005-09-21 2010-10-14 Markus Zahn Systems and methods for tuning properties of nanoparticles
KR20090038337A (ko) * 2007-10-15 2009-04-20 재단법인서울대학교산학협력재단 무기계 나노입자를 수계 매질에 분산시키는 생체적합성분산 안정화제
WO2016004061A1 (en) * 2014-06-30 2016-01-07 University Of Washington Mri signal supression agents, compositions, and methods
US10466326B2 (en) * 2015-05-15 2019-11-05 Stc. Unm Quantitative [Fe]-MRI (femri) of anti-PSMA-conjugated SPIONs based on PSMA expression levels

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3935187A (en) * 1973-10-19 1976-01-27 Standard Brands Incorporated Process for depolymerizing amylaceous polymers
US4501726A (en) * 1981-11-12 1985-02-26 Schroeder Ulf Intravascularly administrable, magnetically responsive nanosphere or nanoparticle, a process for the production thereof, and the use thereof
US4452773A (en) * 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
GB8408127D0 (en) * 1984-03-29 1984-05-10 Nyegaard & Co As Contrast agents
US4767611A (en) * 1984-07-03 1988-08-30 Gordon Robert T Method for affecting intracellular and extracellular electric and magnetic dipoles
US4849210A (en) * 1985-05-08 1989-07-18 Molecular Biosystems, Inc. Magnetic resonance imaging of liver and spleen with superparamagnetic contrast agents
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
US5314679A (en) * 1986-07-03 1994-05-24 Advanced Magnetics Inc. Vascular magnetic resonance imaging agent comprising nanoparticles
US4827945A (en) * 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US5069216A (en) * 1986-07-03 1991-12-03 Advanced Magnetics Inc. Silanized biodegradable super paramagnetic metal oxides as contrast agents for imaging the gastrointestinal tract
US4925678A (en) * 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
DE3709851A1 (de) * 1987-03-24 1988-10-06 Silica Gel Gmbh Adsorptions Te Nmr-diagnostische fluessigkeitszusammensetzungen
US5358702A (en) * 1990-04-10 1994-10-25 Unger Evan C Methoxylated gel particle contrast media for improved diagnostic imaging
JP2921984B2 (ja) * 1991-01-19 1999-07-19 名糖産業株式会社 磁性金属酸化物超微粒子含有組成物
US5225282A (en) * 1991-12-13 1993-07-06 Molecular Bioquest, Inc. Biodegradable magnetic microcluster comprising non-magnetic metal or metal oxide particles coated with a functionalized polymer
EP0580878B1 (en) * 1992-06-01 1996-01-10 BASF Aktiengesellschaft The use of dispersions of magneto-ionic particles as MRI contrast media
US5349957A (en) * 1992-12-02 1994-09-27 Sterling Winthrop Inc. Preparation and magnetic properties of very small magnetite-dextran particles
WO1994021240A2 (de) * 1993-03-17 1994-09-29 Silica Gel Ges.M.B.H Superparamagnetische teilchen, verfahren zu ihrer herstellung und verwendung derselben
DE4428851C2 (de) * 1994-08-04 2000-05-04 Diagnostikforschung Inst Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie
JPH10506121A (ja) * 1994-09-27 1998-06-16 ニコムド イメージング エイ／エス コントラスト剤
US6423296B1 (en) * 1996-01-10 2002-07-23 Amersham Health As Constrast media

Also Published As

Publication number Publication date
CN1219135A (zh) 1999-06-09
DE69717269T2 (de) 2003-08-28
AU704926B2 (en) 1999-05-06
CA2250818A1 (en) 1997-10-09
AU2172197A (en) 1997-10-22
US5855868A (en) 1999-01-05
EP0896546A2 (en) 1999-02-17
WO1997036617A2 (en) 1997-10-09
EP0896546B1 (en) 2002-11-20
WO1997036617A3 (en) 1998-02-26
IL126412A0 (en) 1999-05-09
ATE228017T1 (de) 2002-12-15
JP2000507567A (ja) 2000-06-20
EA199800881A1 (ru) 1999-04-29
DE69717269D1 (de) 2003-01-02
ES2188924T3 (es) 2003-07-01
JP4361970B2 (ja) 2009-11-11
NO984555L (no) 1998-09-29
KR20000005194A (ko) 2000-01-25
EA000796B1 (ru) 2000-04-24

Similar Documents

Publication Publication Date Title
ZA945038B (en) Image contrast enhancing composition
ATE142891T1 (de) Vaskulares magnetisches bildformungsverfahren
HK1002102A1 (en) Contrast agents consisting of galactose particles and an amphiphilic carboxylic acid
HK18094A (en) Use of ferromagnetic particles in contrast agents for nmr imaging and contrast agents
ATE441438T1 (de) Verfahren und kit zur bilderzeugung von organen und geweben, worin markierte antikírper verwendet werden
NL300177I2 (nl) NMR contrastmiddelen voor het lever-galsysteem.
UA27760C2 (uk) Композиція у вигляді наночасток і спосіб її одержання
NO984555L (no) T1- Lever
ATE99544T1 (de) Liposomale radiologische kontrastmittel.
GB9716365D0 (en) Improvements in or relating to magnetic resonance imaging
ES2117670T3 (es) Derivado de hidroxamato e hidrazida de poliaminas y su uso medico como agentes quelantes.
ATE132758T1 (de) Anwendung von dispersionen von magneto-ionischen partikeln in mri-kontrast-mitteln
EP0948361A4 (en) MAGNETIC RESONANCE BLOOD POOL IMAGING AGENTS
FI970789A (fi) Hyvin puhtaita ferromagneettisia rautaoksidipigmenttejä
UA41932C2 (uk) Засіб для ямр-томографії
NO904337L (no) Kontrastmidler for magnetisk resonansavbildning.
KR930700165A (ko) 조영제

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application